Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Emily Bodnar maintains a Buy rating on First Tracks Biotherapeutics (TRAX) with a $30 price target. The recommendation is driven by strengthened validation of the IL-15/CD122 pathway, supported by Teva's positive vitiligo data and ANB033's differentiated mechanism. Upcoming Phase 1b celiac disease results in Q4 2026 are expected to clarify competitive dynamics, supporting a favorable risk-reward profile for the stock.
In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, with a price target of $30.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Emily Bodnar’s rating is based on the strengthening validation of the IL-15/CD122 pathway in immune-mediated skin and gastrointestinal diseases, highlighted by Teva’s encouraging Phase 1b vitiligo results with TEV-’408 and the mechanistic overlap with First Tracks’ lead asset ANB033. She views ANB033’s differentiated CD122 antagonism, which has shown stronger preclinical suppression of key cytotoxic T-cell activity versus competitive agents, as positioning the company well for future indications that share similar disease biology, even beyond vitiligo.
Emily Bodnar has given his Buy rating due to a combination of factors including upcoming clinical catalysts in celiac disease, where ANB033’s Phase 1b data are expected in 4Q26 and will read out alongside comparable programs such as TEV-’408 and Forte’s FB102, helping clarify competitive dynamics and the risk–benefit profile of the class. In her view, the convergence of positive external data, robust mechanistic rationale, and multiple near- to medium-term readouts in closely related indications supports a favorable risk–reward for TRAX and justifies a Buy recommendation.